4-way competition in NOAC market, well-played by Eliquis and Lixiana

While 4 products are settled in the novel oral anticoagulant(NOAC) market, competition is expected to get fiercer.

Bayer’s Xarelto(rivaroxaban) gained the summit of the market; BMS’s Eliquis(apixaban) and a new strong competitor Daiichi Sankyo’s Lixiana(edoxaban) continued a growth; Boehringer Ingelheim’s Pradaxa(dabigatran) recorded a relatively poor performance.

According to the industry co...